Demand has broadened across independent fronts: growth is now coming from several distinct, currently-producing sources
The model's full reasoning — Q2 2018 call → NOWe need answer only YES or NO. Need evaluate transcript. Question asks: Does management describe current growth carried by several distinct independent sources at same time at least three genuinely different engines each already producing real current business, and breadth recent/building, with several sources still ahead? Need use only transcript. We need parse. Company Alnylam, RNAi therapeutics. At time Q2 2018, patisiran not yet approved (PDUFA imminent, CHMP positive). Revenue from collaborations, milestones. Pipeline late-stage. They talk about commercial readiness, launches upcoming. But current growth? They have collaboration revenue from Sanofi Genzyme, milestones. They have pipeline programs. But question asks "current growth is being carried by SEVERAL DISTINCT, INDEPENDENT SOURCES AT THE SAME TIME — at least three genuinely different engines such as different products or offerings, different customer types or end markets, different geographies or channels, or different ways of earning — EACH of which is described as ALREADY PRODUCING REAL CURRENT BUSINESS (actual revenue, orders, customers, volumes, or activity in the recent period, described with concrete substance) rather than being a plan or hope, AND does management convey that this breadth is itself recent or building — that the company was until recently narrower, with growth carried by fewer engines — so that several of these sources still have most of their contribution ahead?" Need determine if management describes such. They discuss pipeline: patisiran (not approved yet, but EAP 200 patients, CHMP positive), givosiran (Phase 3 interim upcoming, enrollment ahead), lumasiran (Phase 1/2 data, Phase 3 starting), TTRsc02 (Phase 3 starting), inclisiran (partner MedCo), fitusiran (partner Sanofi), cemdisiran (slower enrollment), CNS preclinical. But current business? Revenue from collaborations: $29.9M collaboration revenue, $23.1M from Sanofi Genzyme alliance, $6.8M other. Milestone payment from Sanofi Genzyme upon dosing first patient in ATLAS Phase 3 for fitusiran. So current revenue is from collaborations, not product sales. They are pre-commercial. They have no approved product yet. They have EAP providing patisiran to >200 patients, but that's not revenue? Expanded access program, free drug. They have Alnylam Act genetic testing 6,700 individuals, 460 patients identified.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| E | Eni S.p.A. | Q1 2024 | 2024-04-24 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PSFE | Paysafe Limited | Q4 2023 | 2024-03-07 | C+ |
| FRPH | FRP Holdings, Inc. | Q4 2023 | 2024-03-07 | C+ |
| GTLB | GitLab Inc. | Q4 2024 | 2024-03-04 | C+ |
| INTR | Inter & Co, Inc. | Q4 2023 | 2024-02-08 | B+ |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ANGO | AngioDynamics, Inc. | Q1 2024 | 2023-10-04 | B |
| CTLP | Cantaloupe, Inc. | Q4 2023 | 2023-09-06 | B+ |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| ZOM | Zomedica Corp. | Q2 2023 | 2023-08-10 | C |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| INTT | inTEST Corporation | Q2 2023 | 2023-08-04 | A |
| FOUR | Shift4 Payments, Inc. | Q2 2023 | 2023-08-03 | B+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| PERI | Perion Network Ltd. | Q2 2023 | 2023-08-02 | A |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| EDU | New Oriental Education & Technology Grou | Q3 2023 | 2023-04-19 | B |
| ISRG | Intuitive Surgical, Inc. | Q4 2022 | 2023-01-24 | C |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| UGRO | urban-gro, Inc. | Q1 2022 | 2022-05-13 | D |
| XMTR | Xometry, Inc. | Q1 2022 | 2022-05-11 | B+ |
| CLAR | Clarus Corporation | Q1 2022 | 2022-05-09 | B |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| WSC | WillScot Mobile Mini Holdings Corp. | Q4 2021 | 2022-02-25 | B+ |
| LMND | Lemonade, Inc. | Q4 2021 | 2022-02-24 | D |
| SNOW | Snowflake Inc. | Q3 2022 | 2021-12-01 | A |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| BRAG | Bragg Gaming Group Inc. | Q3 2021 | 2021-11-08 | B+ |
| ENV | Envestnet, Inc. | Q3 2021 | 2021-11-08 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| CROX | Crocs, Inc. | Q3 2021 | 2021-10-21 | B+ |
| DG | Dollar General Corporation | Q2 2021 | 2021-08-26 | A |
| ZIM | ZIM Integrated Shipping Services Ltd. | Q2 2021 | 2021-08-18 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| Z | Zillow Group, Inc. | Q2 2021 | 2021-08-05 | B |
| NOV | NOV Inc. | Q2 2021 | 2021-07-28 | C+ |
| STRA | Strategic Education, Inc. | Q2 2021 | 2021-07-28 | C |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| BCO | The Brink's Company | Q3 2018 | 2018-10-24 | C |
| NDLS | Noodles & Company | Q3 2018 | 2018-10-23 | B+ |
| AUDC | AudioCodes Ltd. | Q3 2018 | 2018-10-23 | A |
| YEXT | Yext, Inc. | Q2 2019 | 2018-08-30 | C+ |
| TNC | Tennant Company | Q2 2018 | 2018-07-25 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| ST | Sensata Technologies Holding plc | Q2 2017 | 2017-07-25 | B+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| HUBB | Hubbell Incorporated | Q2 2017 | 2017-07-25 | B+ |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| PPSI | Pioneer Power Solutions, Inc. | Q4 2016 | 2017-03-10 | B |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| LGND | Ligand Pharmaceuticals Incorporated | Q4 2016 | 2017-02-23 | C+ |
| PYPL | PayPal Holdings, Inc. | Q4 2016 | 2017-01-26 | B+ |
| PNFP | Pinnacle Financial Partners, Inc. | Q2 2016 | 2016-07-20 | B |
| BX | Blackstone Inc. | Q1 2016 | 2016-04-21 | B |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
GDRX · Q2 2022 → YESThe question is about whether management describes the company's CURRENT growth as being carried by SEVERAL DISTINCT, INDEPENDENT SOURCES AT THE SAME TIME — at least three genuinely different engines,...YES The transcript shows management describing current growth as carried by multiple distinct engines: prescription transactions (still the core but with recent challenges), subscriptions revenue (82% YoY growth), and Pharma Manufacturer Solutions (more than doubled YoY). They explicitly frame the diversification as a recent development, noting that other offerings now make up 30% of revenue compared to 5% just three years ago, with several sources like subscriptions and pharma still having most of their contribution ahead due to significant TAM and low penetration. This breadth is presented as newly meaningful for the company, reflecting the early stage of these newer fronts rather than a long-standing diversified business.
TOUR · Q4 2017 → YESThe question is about whether management describes current growth being carried by several distinct, independent sources at the same time — at least three genuinely different engines — each already pr...YES Management describes current growth as carried by multiple distinct, independent engines that are already producing real revenue and activity: packaged tours (organized and self-guided), financial services and commissions, offline retail stores (18% of GMV in Q4 2017, launched 2016), direct procurement (40% of GM 2017), and corporate TMC services (more than 200% YoY growth). They explicitly note diversification of sales channels (online, mobile, loyalty, offline, B2B/corporate) and that the company was narrower until recently, with offline retail and corporate TMC expanding in 2016–2017 while local operators remain small but growing.
CYBR · Q3 2021 → YESThe question is about whether management describes current growth being carried by several distinct, independent sources at the same time — at least three genuinely different engines — each producing ...YES The transcript shows management describing current growth as driven by multiple distinct, independent engines operating simultaneously: record SaaS bookings and subscription ARR growth (131%), the Identity Security platform centered on Privileged Access Management (PAM) and Privilege Cloud with new logos over 230, EPM with another record quarter, Access and DevSecOps offerings, plus expansion across geographies (every region growing) and verticals (new logos in law firms, software, oil & gas, retailers, government). These are presented as real, current business with concrete metrics and customer examples, not plans.